File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL

Conference Paper: Impact of Pneumococcal Conjugate Vaccines (PCV) on the incidence of community acquired pneumonia (CAP) in the UK

TitleImpact of Pneumococcal Conjugate Vaccines (PCV) on the incidence of community acquired pneumonia (CAP) in the UK
Authors
KeywordsChild
Pneumococcal conjugate vaccine
Respiratory tract infections
Pneumococcal infections
Issue Date2013
PublisherThe Pharmaceutical Society of Hong Kong. The Journal's web site is located at http://www.pshk.hk/main.php?id=62
Citation
The 8th Asian Conference on Pharmacoepidemiology (ACPE 2013), Hong Kong, China, 25-27 October 2013. In Hong Kong Pharmaceutical Journal, 2013, v. 20 n. 3, p. 149 How to Cite?
AbstractAims/Objectives: Heptavalent PCV (PCV7) was introduced into the UK vaccination schedule in September 2006 followed by 13-valent PCV (PCV13) in April 2010. In the US and Europe PCV7 reduced the incidence of invasive pneumococcal disease in children aged <5 years. Hospital pneumonia admission rates in England declined by 19% in the 2 years post-introduction (Koshy et al., 2010). We assessed the impact of PCVs on primary care diagnoses of CAP and associated antibiotic prescribing in children. Methods: A descriptive cohort study was conducted using The Health Improvement Network database of anonymised patient health records for 5% of the UK population. The study population comprised children aged <16 years with ≥6 months’ data and ≥1 pneumonia diagnosis recorded between 1 January 2002 and 31 December 2010. The duration of an episode of CAP was defi ned as 30 days. Annual incidences of CAP and antibiotic prescribing were calculated. Results: CAP incidence declined by 13.3% for children aged <16 years between January 2006 and December 2010 from 1.07 episodes/1000 person-years (PY) to 0.92/1000 PY; the largest reductions were in younger age bands (28.3% in <2 years; 20.3% in 2-5 years; 27.8% in 6-10 years). Antibiotic prescribing decreased by 10.3% overall; however the steepest decline (44.2%) was seen in children aged <2 years from 0.74 treated-episodes/1000 PY in 2006 to 0.41/1000 PY in 2010. Conclusion: PCVs have reduced the incidence of CAP diagnoses and antibiotic prescribing for CAP since their introduction; this is most evident in the main target group of young children <2 years.
DescriptionConference Theme: Applying pharmacoepidemiology to improve health care in Asia
Oral Presentation - Respiratory Matters
Persistent Identifierhttp://hdl.handle.net/10722/204458
ISSN

 

DC FieldValueLanguage
dc.contributor.authorMurray, MLen_US
dc.contributor.authorHsia, YFen_US
dc.contributor.authorEl-Turki, Aen_US
dc.contributor.authorSharland, Men_US
dc.contributor.authorSaxena, Sen_US
dc.contributor.authorLong, Pen_US
dc.contributor.authorWong, ICKen_US
dc.date.accessioned2014-09-19T23:52:23Z-
dc.date.available2014-09-19T23:52:23Z-
dc.date.issued2013en_US
dc.identifier.citationThe 8th Asian Conference on Pharmacoepidemiology (ACPE 2013), Hong Kong, China, 25-27 October 2013. In Hong Kong Pharmaceutical Journal, 2013, v. 20 n. 3, p. 149en_US
dc.identifier.issn1727-2874-
dc.identifier.urihttp://hdl.handle.net/10722/204458-
dc.descriptionConference Theme: Applying pharmacoepidemiology to improve health care in Asia-
dc.descriptionOral Presentation - Respiratory Matters-
dc.description.abstractAims/Objectives: Heptavalent PCV (PCV7) was introduced into the UK vaccination schedule in September 2006 followed by 13-valent PCV (PCV13) in April 2010. In the US and Europe PCV7 reduced the incidence of invasive pneumococcal disease in children aged <5 years. Hospital pneumonia admission rates in England declined by 19% in the 2 years post-introduction (Koshy et al., 2010). We assessed the impact of PCVs on primary care diagnoses of CAP and associated antibiotic prescribing in children. Methods: A descriptive cohort study was conducted using The Health Improvement Network database of anonymised patient health records for 5% of the UK population. The study population comprised children aged <16 years with ≥6 months’ data and ≥1 pneumonia diagnosis recorded between 1 January 2002 and 31 December 2010. The duration of an episode of CAP was defi ned as 30 days. Annual incidences of CAP and antibiotic prescribing were calculated. Results: CAP incidence declined by 13.3% for children aged <16 years between January 2006 and December 2010 from 1.07 episodes/1000 person-years (PY) to 0.92/1000 PY; the largest reductions were in younger age bands (28.3% in <2 years; 20.3% in 2-5 years; 27.8% in 6-10 years). Antibiotic prescribing decreased by 10.3% overall; however the steepest decline (44.2%) was seen in children aged <2 years from 0.74 treated-episodes/1000 PY in 2006 to 0.41/1000 PY in 2010. Conclusion: PCVs have reduced the incidence of CAP diagnoses and antibiotic prescribing for CAP since their introduction; this is most evident in the main target group of young children <2 years.-
dc.languageengen_US
dc.publisherThe Pharmaceutical Society of Hong Kong. The Journal's web site is located at http://www.pshk.hk/main.php?id=62-
dc.relation.ispartofHong Kong Pharmaceutical Journalen_US
dc.subjectChild-
dc.subjectPneumococcal conjugate vaccine-
dc.subjectRespiratory tract infections-
dc.subjectPneumococcal infections-
dc.titleImpact of Pneumococcal Conjugate Vaccines (PCV) on the incidence of community acquired pneumonia (CAP) in the UKen_US
dc.typeConference_Paperen_US
dc.identifier.emailWong, ICK: wongick@hku.hken_US
dc.identifier.authorityWong, ICK=rp01480en_US
dc.identifier.hkuros239886en_US
dc.identifier.volume20en_US
dc.identifier.issue3en_US
dc.identifier.spage149en_US
dc.identifier.epage149en_US
dc.publisher.placeHong Kong-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats